Trial reportInvestigational new drugs2017
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Trial report in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials.Frontiers in oncology · 2021Pooled it
- Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.JAMA network open · 2019Pooled it
- A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2018Trial
- Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.Investigational new drugs · 2017Trial
- Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Unlocking the Potential of Polysaccharides for the Treatment of Lung Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Review
- Role of Trained Immunity in Heath and Disease.Current cardiology reports · 2025Review
- The causes and consequences of trained immunity in myeloid cells.Frontiers in immunology · 2024Review
- Microbial underdogs: exploring the significance of low-abundance commensals in host-microbe interactions.Experimental & molecular medicine · 2023Review
- Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1.Science immunology · 2023Article
- How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?BMJ oncology · 2023Review
- The mechanisms and cross-protection of trained innate immunity.Virology journal · 2022Review
- From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases.International journal of molecular sciences · 2022Review
- Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.Journal of experimental & clinical cancer research : CR · 2021Review
- Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer.Thoracic cancer · 2021Article
- Edible Mushrooms and Beta-Glucans: Impact on Human Health.Nutrients · 2021Review
- Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling.Cell reports · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction BTH1677, a 1,3-1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with cetuximab/carboplatin/paclitaxel in untreated stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Methods Patients were randomized 2:1 to the BTH1677 arm (N=60; BTH1677, 4 mg/kg, weekly; cetuximab, initial dose 400 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.